Study Design: This interventional study is randomized and follows a parallel assignment model. It is double-blind, meaning neither participants nor the care providers, investigators, or outcome ...

A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study.

A new study by University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about ...

Enzalutamide monotherapy demonstrated significant treatment response among men on active surveillance for low- or intermediate-risk localized prostate cancer, according to phase 2 study results ...

"Enzalutamide in combination with ADT, if approved in this setting, has the potential to become new standard of care for patients with high-risk BCR," said Shore.

XTANDI (enzalutamide) is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with metastatic hormone-sensitive prostate cancer ...

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Today, Astellas Pharma Canada, Inc. announced that XTANDI® (enzalutamide) is now funded by the Ontario Drug Benefit Program under the Exceptional Access Program for the treatment of patients with ...

In a phase 3 clinical trial by Pfizer, treatment with talazoparib and enzalutamide lowered the risk of prostate cancer progression or death by 37%.

In a study of men with nmHSPC and high-risk BCR, enzalutamide plus leuprolide lowered metastasis risk compared with leuprolide plus placebo.

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients.